Methods for treating AVM's using radio active compositions

• US 6,333,020 B1
• Filed: 05/13/1999
• Issued: 12/25/2001
• Est. Priority Date: 05/13/1999
• Status: Expired due to Term

• Current Assignee: Covidien LP (Medtronic Plc)
• Original Assignee: Micro Therapeutics, Inc. (Medtronic Plc)
• Inventors: Wallace, George, Greff, Richard J.
• Primary Examiner(s): JONES, DAMERON LEVEST
• Application Number:
  US09/311,803
• Time in Patent Office: 957 Days
• Field of Search: 424/1.11, 424/1.65, 424/1.69, 424/9.1, 424/9.2, 424/9.3, 424/9.4, 424/9.5, 424/9.6, 424/450, 424/489, 424/1.29, 424/1.33, 424/1.25, 604/264, 600/3, 600/4, 514/944
• US Class Current: 424/1.25
• CPC Class Codes: A61K 51/1217 Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

Disclosed are methods for treating AVMs in a mammal by use of a radiation composition.

Claims

1. A method for treating an arteriovenous malformation (AVM) in a mammal which method comprises:

(a) selecting a fluidic composition comprising a biocompatible polymer, a biocompatible solvent which solubilizes said polymer and a water insoluble radioisotope wherein said biocompatible solvent is selected from the group consisting of dimethylsulfoxide, ethanol, ethyl lactate and acetone; and

(b) injecting an effective amount of said composition into one or more vascular sites of said mammal which lead to or are within the AVM under conditions wherein a solid mass is formed which solid mass ablates at least part of the AVM wherein said solid mass comprises the water insoluble polymer and the radioisotope

and further wherein the radioactivity of the radioisotope is employed in an amount effective to inhibit regrowth of the AVM and to further ablate the AVM.

3. The method according to claim 1 wherein said water insoluble biocompatible polymer is selected from the group consisting of biodegradable and non-biodegradable polymers.

4. The method according to claim 3 wherein said biocompatible polymer is non-biodegradable.

5. The method according to claim 4 wherein said non-biodegradable biocompatible polymer is selected from the group consisting of cellulose acetates, ethylene vinyl alcohol copolymers, hydrogels, polyacrylonitrile, polyvinylacetate, cellulose acetate butyrate, nitrocellulose, copolymers of urethane/carbonate, copolymers of styrene/maleic acid, and mixtures thereof.

6. The method according to claim 5 wherein said non-biodegradable biocompatible polymer is a copolymer of ethylene and vinyl alcohol.

7. The method according to claim 3 wherein said biocompatible polymer is biodegradable.

8. The method according to claim 7 wherein said biodegradable biocompatible polymer is a linear-chain polymer selected from the group consisting of polylactides, polyglycolides, polycaprolactones, polyanhydrides, polyamides, polyurethanes, polyesteramides, polyorthoesters, polydioxanones, polyacetals, polyketals, polycarbonates, polyorthocarbonates, polyphosphazenes, polyhydroxybutyrates, polyhydroxyvalerates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid), poly(amino acids), polyvinylpyrrolidone, polyethylene glycol, polyhydroxycellulose, chitin, chitosan, copolymers, terpolymers thereof, gelatin, fibrin and collagen.

9. The method according to claim 1 wherein said radioisotope is selected from the group consisting of ⁹⁰yttrium, ¹⁹²iridium, ¹⁹⁸gold, ¹²⁵iodine, ¹³⁷cesium, ⁶⁰cobalt, ⁵⁵cobalt, ⁵⁶cobalt, ⁵⁷cobalt, ⁵⁷magnesium, ⁵⁵iron, ³²phosphorus, ⁹⁰strontium, ⁸¹rubidium, ²⁰⁶bismuth, ⁶⁷gallium, ⁷⁷bromine, ¹²⁹cesium, ⁷³selenium, ⁷²selenium, ⁷²arsenic, ¹⁰³palladium, ²⁰³lead, ¹¹¹lindium, ⁵²iron, ¹⁶⁷thulium, ⁵⁷nickel, ⁶²zinc, ⁶¹copper, ²⁰¹thallium and ¹²³iodine.

10. The method according to claim 1 which further comprises a non-radioactive contrast agent.

11. The method according to claim 10 wherein said non-radioactive contrast agent is water soluble.

12. The method according to claim 11 wherein said water soluble non-radioactive contrast agent is selected from the group consisting of metrizamide, iopamidol, iothalamate sodium, iodomide sodium, and meglumine.

13. The method according to claim 10 wherein said non-radioactive contrast agent is water insoluble.

14. The method according to claim 13 wherein said water insoluble cointrast agent is tantalum, tantalum oxide, barium sulfate, tungsten, gold and platinum.

15. The method according to claim 1 wherein said fluidic composition comprises from about 0.1 to about 35 weight percent of a water insoluble radioisotope having from a radioactive content of from about 0.1 microcurie to about 35 microcurie.

2. A method for treating an arteriovenous malformation (AVM) in a mammal which method comprises:

(a) selecting a fluidic composition comprising a biocompatible polymer, dimethlysulfoxide which solubilizes said polymer and a water insoluble radioisotope; and

(b) injecting an effective amount of said composition into one or more vascular sites leading to or within the AVM under conditions wherein a solid mass is formed which solid mass ablates at least part of the AVM

wherein the radioactivity of the radioisotope is employed in an amount effective to inhibit regrowth of the AVM and to further ablate the AVM.